News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
494,348 Results
Type
Article (11836)
Company Profile (143)
Press Release (482367)
Multimedia
Podcasts (52)
Webinars (7)
Section
Business (169941)
Career Advice (390)
Deals (26321)
Drug Delivery (27)
Drug Development (55063)
Employer Resources (34)
FDA (10121)
Job Trends (8950)
News (243275)
Policy (18937)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (587)
Accelerated approval (30)
ADA (20)
Adcomms (7)
Allergies (99)
Alliances (33782)
ALS (111)
Alzheimer's disease (1016)
Antibody-drug conjugate (ADC) (320)
Approvals (10714)
Artificial intelligence (349)
ASCO (185)
Autoimmune disease (235)
Automation (29)
Bankruptcy (269)
Belgium (1)
Best Places to Work (7175)
BIO (36)
Biologics (9)
BIOSECURE Act (3)
Biosimilars (123)
BioSpace Insights (24)
Biotechnology (91)
Bispecific (1)
Bladder cancer (154)
Brain cancer (33)
Breast cancer (541)
Cancer (3934)
Cardiovascular disease (266)
Career advice (317)
Career pathing (6)
CAR-T (187)
CDC (21)
CDMO (53)
Celiac Disease (1)
Cell therapy (514)
Cervical cancer (39)
Clinical research (49170)
Collaboration (1324)
Commercialization (4)
Compensation (1536)
Complete response letters (37)
COVID-19 (1610)
CRISPR (67)
C-suite (883)
Cystic fibrosis (90)
Data (5935)
Decentralized trials (1)
Denatured (4)
Depression (107)
Dermatology (68)
Diabetes (364)
Diagnostics (4282)
Digital health (40)
Diversity (2)
Diversity, equity & inclusion (11)
Drug discovery (171)
Drug pricing (74)
Drug shortages (3)
Duchenne muscular dystrophy (191)
Earnings (74242)
Editorial (18)
Employer branding (7)
Employer resources (33)
Events (88796)
Executive appointments (757)
FDA (12899)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (1009)
Gene editing (139)
Generative AI (15)
Gene therapy (389)
GLP-1 (415)
Government (1477)
Grass and pollen (2)
Guidances (285)
Healthcare (9714)
Hematology (95)
HIV (60)
Huntington's disease (26)
IgA nephropathy (68)
Immunology and inflammation (131)
Immuno-oncology (70)
Indications (164)
Infectious disease (1836)
Inflammatory bowel disease (138)
Inflation Reduction Act (7)
Influenza (91)
Intellectual property (264)
Interviews (52)
IPO (12485)
IRA (21)
Job creations (2123)
Job search strategy (299)
JPM (14)
Kidney cancer (17)
Labor market (11)
Layoffs (115)
Leadership (4)
Legal (5399)
Licensing (18)
Liver cancer (47)
Longevity (19)
Lung cancer (563)
Lymphoma (275)
Machine learning (29)
Management (10)
Manufacturing (602)
Marketing (8)
MASH (126)
Medical affairs (2)
Medical device (8710)
Medtech (8870)
Mergers & acquisitions (14907)
Metabolic disorders (857)
mRNA (145)
Multiple sclerosis (109)
NASH (5)
Neurodegenerative disease (241)
Neuropsychiatric disorders (44)
Neuroscience (1923)
NextGen: Class of 2026 (3268)
Non-profit (906)
Now hiring (2)
Obesity (329)
Opinion (63)
Ovarian cancer (163)
Pain (183)
Pancreatic cancer (209)
Parkinson's disease (209)
Partnered (12)
Patents (521)
Patient recruitment (539)
Patient selection (2)
Peanut (32)
People (42659)
Peptides (3)
Pharmaceutical (30)
Pharmacy benefit managers (11)
Phase 1 (15901)
Phase 2 (21944)
Phase 3 (15107)
Pipeline (7820)
Policy (97)
Postmarket research (1596)
Preclinical (6658)
Press Release (34)
Prostate cancer (206)
Psychedelics (14)
Radiopharmaceuticals (201)
Rare diseases (648)
Real estate (3132)
Recruiting (15)
Regenerative medicine (2)
Regulatory (15552)
Reports (23)
Research institute (693)
Resumes & cover letters (60)
Rett syndrome (42)
RNA editing (5)
RSV (69)
Schizophrenia (106)
Series A (179)
Series B (133)
Service/supplier (5)
Sickle cell disease (74)
Special edition (9)
Spinal muscular atrophy (93)
Sponsored (6)
Startups (2175)
Stomach cancer (3)
Supply chain (56)
Tariffs (34)
The Weekly (47)
Vaccines (756)
Venture capital (35)
Weight loss (162)
Women's health (91)
Date
Today (69)
Last 7 days (302)
Last 30 days (1453)
Last 365 days (19703)
2026 (13979)
2025 (19862)
2024 (23447)
2023 (26997)
2022 (35461)
2021 (38229)
2020 (34205)
2019 (23792)
2018 (17964)
2017 (19322)
2016 (18447)
2015 (24526)
2014 (21872)
2013 (18312)
2012 (20410)
2011 (20658)
2010 (20451)
Location
Africa (285)
Alabama (78)
Alaska (2)
Arizona (311)
Arkansas (11)
Asia (18739)
Australia (2201)
California (12401)
Canada (3241)
China (629)
Colorado (499)
Connecticut (436)
Delaware (217)
Europe (27084)
Florida (1881)
Georgia (394)
Hawaii (3)
Idaho (46)
Illinois (735)
India (53)
Indiana (324)
Iowa (16)
Japan (428)
Kansas (104)
Kentucky (33)
Louisiana (28)
Maine (26)
Maryland (1288)
Massachusetts (8181)
Michigan (315)
Minnesota (577)
Mississippi (5)
Missouri (82)
Montana (21)
Nebraska (11)
Nevada (122)
New Hampshire (60)
New Jersey (2733)
New Mexico (12)
New York (2931)
North Carolina (1322)
North Dakota (4)
Northern California (6247)
Ohio (293)
Oklahoma (14)
Oregon (18)
Pennsylvania (2324)
Puerto Rico (21)
Rhode Island (32)
South America (456)
South Carolina (78)
South Dakota (1)
Southern California (5147)
Tennessee (126)
Texas (2008)
United States (40375)
Utah (372)
Vermont (1)
Virginia (163)
Washington D.C. (42)
Washington State (960)
West Virginia (2)
Wisconsin (76)
Wyoming (1)
494,348 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist.
July 15, 2026
·
1 min read
·
Gabrielle Masson
Antibody-drug conjugate (ADC)
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of the pharma.
September 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - September 15, 2026
September 15, 2026
·
3 min read
Press Releases
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - September 8, 2026
September 8, 2026
·
3 min read
Earnings
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.
August 4, 2026
·
1 min read
·
Annalee Armstrong
Lung cancer
Pfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buy
Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.
June 23, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 billion in sales.
March 17, 2026
·
1 min read
·
Annalee Armstrong
Earnings
Pfizer is a 2029 story but Q126 lays foundation for growth
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
May 5, 2026
·
3 min read
·
Annalee Armstrong
Cardiovascular disease
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
May 12, 2026
·
2 min read
·
Tristan Manalac
Earnings
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
February 3, 2026
·
4 min read
·
Annalee Armstrong
1 of 49,435
Next
